Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

The Investigator hypothesize that Dapagliflozin will improve EPC number and function AND Saxagliptin in addition to Dapagliflozin (additive effect) may improve EPC number and function even more than Dapa alone, compared to placebo. The Investigator propose a 3-arm randomized, parallel group, longitudinal study of 16-week intervention duration. Participants will be …

angina pectoris
saxagliptin
dapagliflozin
insulin
glycosylated hemoglobin
  • 15 views
  • 25 Jan, 2021
  • 1 location
HF Prevalence and Evolution of HF in DM II Patients at High Risk

This is an epidemiological, single-country, multicenter, 2-year prospective cohort study based on both primary and secondary data collection, which will include a representative sample of 300 eligible T2DM patients managed in real-life settings in Greece. A cross-sectional approach will be applied for addressing the primary objective of the study (prevalence …

  • 0 views
  • 01 May, 2021
  • 10 locations
Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

females who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2 (SGLT2) inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy and

bladder cancer
cancer
bladder tumor
metformin
  • 0 views
  • 21 Apr, 2021
  • 4 locations
Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)

GIOIA represents a multicenter pragmatic prospective cohort study, aimed at evaluating the effects of SGLT2 inhibitors currently marketed (dapagliflozin, canagliflozin, empagliflozin) on markers

dapagliflozin
canagliflozin
empagliflozin
metformin
sglt2 inhibitor
  • 0 views
  • 22 Jan, 2021
  • 1 location
Human Solute Carrier Family 5 Member 2 (SLC5A2) Deficiency and the Glucagon-Incretin Axis

Sodium-glucose-cotransporter 2 (SGLT2) are a new type of oral antidiabetic drugs. SGLT2 inhibitors increase the urinary glucose excretion and thereby decrease blood glucose levels. Beside their

antidiabetic agents
insulin
incretins
glucagon
  • 0 views
  • 23 Jan, 2021
  • 1 location
Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus

: SGLT2 inhibitors +/- Metformin GROUP 2: DPP4 inhibitors +/- Metformin GROUP 3: GLP1-RA + Long-acting insulin +/- Metformin GROUP 4: SGLT2 inhibitors + DPP4 inhibitors

active treatment
diabetes
renal function
  • 0 views
  • 26 Jan, 2021
  • 1 location